$2.13
1.41% today
Nasdaq, Dec 24, 05:11 pm CET
ISIN
US23666P1012
Symbol
DARE

Dare Bioscience, Inc. Stock price

$2.16
+0.37 20.67% 1M
-0.40 15.63% 6M
-0.96 30.77% YTD
-1.03 32.29% 1Y
-8.28 79.31% 3Y
-15.12 87.50% 5Y
-443.04 99.51% 10Y
-819.84 99.74% 20Y
Nasdaq, Closing price Tue, Dec 23 2025
+0.00 0.00%
ISIN
US23666P1012
Symbol
DARE
Industry

Key metrics

Basic
Market capitalization
$30.9m
Enterprise Value
$15.1m
Net debt
positive
Cash
$23.1m
Shares outstanding
13.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1,028.8 | 78.4
EV/Sales
501.8 | 38.2
EV/FCF
negative
P/B
10.8
Financial Health
Equity Ratio
-27.2%
Return on Equity
67.4%
ROCE
-143.1%
ROIC
-
Debt/Equity
2.5
Financials (TTM | estimate)
Revenue
$30.0k | $393.7k
EBITDA
$-12.5m | -
EBIT
$-13.6m | $-18.4m
Net Income
$-13.5m | $-22.0m
Free Cash Flow
$-6.9m
Growth (TTM | estimate)
Revenue
-98.4% | 3,837.0%
EBITDA
45.9% | -
EBIT
41.3% | 21.7%
Net Income
-273.6% | -442.0%
Free Cash Flow
20.6%
Margin (TTM | estimate)
Gross
127.8%
EBITDA
-45,252.7% | -
EBIT
-49,247.3%
Net
-48,546.9% | -5,575.6%
Free Cash Flow
-24,711.2%
More
EPS
$-1.1
FCF per Share
$-0.5
Short interest
1.4%
Employees
22
Rev per Employee
$0.0
Show more

Is Dare Bioscience, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Dare Bioscience, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Dare Bioscience, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Dare Bioscience, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Dare Bioscience, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.03 0.03
98% 98%
100%
- Direct Costs -0.01 -0.01
200% 200%
-33%
0.04 0.04
43% 43%
133%
- Selling and Administrative Expenses 6.83 6.83
34% 34%
22,767%
- Research and Development Expense 6.78 6.78
54% 54%
22,600%
-13 -13
46% 46%
-41,800%
- Depreciation and Amortization 1.11 1.11
2,675% 2,675%
3,700%
EBIT (Operating Income) EBIT -14 -14
41% 41%
-45,472%
Net Profit -13 -13
274% 274%
-44,833%

In millions USD.

Don't miss a Thing! We will send you all news about Dare Bioscience, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dare Bioscience, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women's sexual health ...
Neutral
Seeking Alpha
about one month ago
Daré Bioscience, Inc. ( DARE ) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns November 17, 2025 12:00 PM EST Company Participants Jennifer Kiang Sabrina Johnson - CEO, President, Principal Financial Officer, Secretary & Director Conference Call Participants Sheryl Kingsberg Jim Simon Presentation Jennifer Kiang All right. Good morning, everyone...
Neutral
Seeking Alpha
about one month ago
Daré Bioscience, Inc. ( DARE ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Johnson - CEO, President, Principal Financial Officer, Secretary & Director Conference Call Participants Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC,...
More Dare Bioscience, Inc. News

Company Profile

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Sabrina Johnson
Employees 22
Founded 2015
Website www.darebioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today